Paul Hastings Advises M42 on Strategic Investment and Partnership With Juvenescence

Paul Hastings (Europe) LLP is advising M42, a global health leader powered by artificial intelligence (AI), technology and genomics, on its strategic investment in longevity biotech leader Juvenescence. As part of this investment, M42 and Juvenescence will form a strategic partnership to identify and develop a pipeline of AI-enabled therapeutics to extend healthy lifespans and advance the treatment of life-threatening diseases.

London corporate partners David Prowse and Dan Hirschovits are leading the Paul Hastings team, along with associates Amelia McGrath, Silas Raggett, Macario Chung and Hugh Odone. The team also includes partners Jane Song and Peter Lindsay and associates Jason Russell and Jordan Hill.

More details on the transaction can be found here.

About Paul Hastings

With widely recognized elite teams across 17 core practices, Paul Hastings is a premier law firm with a culture of excellence focused on providing intellectual capital and superior execution globally to the world’s leading investment banks, asset managers and corporations. For more information, visit www.paulhastings.com.